ConductScience.org, home

Disease · MONDO_0001708

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
PREDNISONECHEMBL635Small moleculePhase 3ClinicalTrials.gov443Drugs and targets
METHYLPREDNISOLONECHEMBL650Small moleculePhase 3ClinicalTrials.gov331Drugs and targets
HYDROXYCHLOROQUINECHEMBL1535Small moleculePhase 3ClinicalTrials.gov222Drugs and targets
PREDNISOLONECHEMBL131Small moleculePhase 3ClinicalTrials.gov220Drugs and targets
MYCOPHENOLIC ACIDCHEMBL866Small moleculePhase 3ClinicalTrials.gov111Drugs and targets
AZITHROMYCINCHEMBL529Small moleculePhase 2ClinicalTrials.gov222Drugs and targets
5-(4-((2S,5S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1H-1,2,4-TRIAZOL-3-AMINECHEMBL4788866Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
ATORVASTATINCHEMBL1487Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
BOSENTANCHEMBL957Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
CYCLOPHOSPHAMIDECHEMBL1200796Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
DAPSONECHEMBL1043Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
ETHAMBUTOLCHEMBL44884Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
LEVOFLOXACINCHEMBL5315124Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
METFORMINCHEMBL1431Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
NAMILUMABCHEMBL1743044AntibodyPhase 2ClinicalTrials.gov111Drugs and targets
PD-360324CHEMBL2109513Phase 2ClinicalTrials.gov110Drugs and targets
PENTOXIFYLLINECHEMBL628Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
RIFAMPINCHEMBL374478Small moleculePhase 2ClinicalTrials.gov111Drugs and targets
(+/-)NICOTINECHEMBL440464Small moleculePhase 1/2ClinicalTrials.gov222Drugs and targets
NICOTINECHEMBL3Small moleculePhase 1/2ClinicalTrials.gov222Drugs and targets

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001708/drugs